Physiological Effects of Grape Seed Extract in Diastolic Heart Failure
NCT01185067 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15
Last updated 2017-06-06
Summary
Diastolic heart failure (also known as "heart failure with normal ejection fraction" or "heart failure with preserved ejection fraction") occurs even though the heart muscle's pumping function is normal. In many cases diastolic heart failure is related to stiffening of the heart and blood vessels in people who have high blood pressure. Current guidelines suggest that patients should limit the salt content of their diet, as too much salty food can cause fluid retention and other problems in diastolic heart failure. Studies in animals with diastolic heart failure suggest that antioxidant chemicals found in grapes can block some of the harmful effects of salty diets. Because it is often difficult for patients with diastolic heart failure to maintain a low salt diet, the investigators are researching the effects of the antioxidant properties of grape seed extract, a natural supplement made from grape seeds. The investigators hypothesize that supplementing the diet with grape seed extract (GSE) can decrease the levels of harmful chemicals and improve heart and blood vessel function in patients with diastolic heart failure and a history of high blood pressure.
The University of Michigan research group plans to enroll 25 patients with a history of high blood pressure and diastolic heart failure in a research study. The study will assess the effects of GSE on hormones and other chemicals that can cause heart and blood vessel damage. The investigators will also study the effects of GSE on the ability of the blood vessels and heart muscles to relax at the proper time and speed. Finally, the investigators will observe how GSE affects participants' overall ability to exercise, quality of life, and blood pressure control. Study participants will be randomly assigned to take either GSE or placebo (looks like but does not contain GSE) capsules twice a day for six weeks. After a two-week break, all subjects will cross over to the opposite group of capsules for an additional six-week period. At the start of the study and at the end of each six-week time period study participants will have non-invasive heart and blood vessel testing, blood work and urine tests, and blood pressure monitoring.
Conditions
- Diastolic Heart Failure
- Hypertensive Heart Disease
- Heart Failure With Preserved Ejection Fraction
- Hypertension
- Oxidative Stress
Interventions
- DRUG
-
grape seed extract (MegaNatural BP, Polyphenolics, Inc.)
Subjects will be randomized in double-blind fashion to either grape seed extract (GSE) or maltodextrin placebo capsules for for 6 weeks. Patient will take 300 mg GSE/placebo twice a day for 6 weeks. Patient will have a 2 week washout period and then cross over to the opposite group for an additional 6 weeks.
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Scott L Hummel, MD, MS · University of Michigan
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-10-31
- Primary Completion
- 2013-11-04
- Completion
- 2014-02-24
Countries
- United States
Study Locations
More Related Trials
-
Intracellular Magnesium and Heart Failure
NCT06353750 ·Status: NOT_YET_RECRUITING
-
Intravenous Allopurinol in Heart Failure
NCT00181155 ·Status: COMPLETED ·Phase: PHASE2
-
Dapagliflozin in Reducing Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction
NCT06510270 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Regression of Fatty Heart by Valsartan Therapy
NCT00745953 ·Status: WITHDRAWN ·Phase: PHASE4
-
Effects of Dietary Nitrate Supplementation on Cardiorespiratory Control in Chronic Heart Failure
NCT02401126 ·Status: COMPLETED ·Phase: PHASE4
-
Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction(HFpEF)
NCT01354613 ·Status: COMPLETED ·Phase: NA
-
Study of the Acute Effects of Triheptanoin in Heart Failure
NCT01787851 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Ketones in Heart Failure With Reduced Ejection Fraction
NCT06195982 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2
-
Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy
NCT04575675 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Dapagliflozin on Cardiorespiratory Parameters in Heart Failure
NCT05770167 ·Status: UNKNOWN
-
Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction
NCT01932606 ·Status: COMPLETED ·Phase: PHASE2
-
Digoxin Withdrawal in Stable Heart Failure
NCT01398371 ·Status: COMPLETED ·Phase: NA
-
Evaluation of GeranylGeranylAcetone in Heart Failure With Preserved Ejection Fraction
NCT05672134 ·Status: COMPLETED ·Phase: PHASE2
-
Midodrine in Heart Failure With Reduced Ejection Fraction With Hypotension
NCT06405555 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)
NCT04363697 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of a Single Oral Dose of KETone Ester ON Exercise Performance in Patients With Chronic Heart Failure
NCT05348460 ·Status: COMPLETED ·Phase: NA
-
Effects of Allopurinol on Diastolic Function in Chronic Heart Failure Patients
NCT00477789 ·Status: COMPLETED ·Phase: PHASE4
-
DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction
NCT05764057 ·Status: RECRUITING ·Phase: PHASE3
-
Effectiveness of CRD-740 in Heart Failure
NCT05409183 ·Status: TERMINATED ·Phase: PHASE2
-
Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure
NCT02862600 ·Status: TERMINATED ·Phase: PHASE2
-
DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction
NCT03877237 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Dietary Nitrate Ingestion in Heart Failure
NCT03511248 ·Status: TERMINATED ·Phase: PHASE2
-
The Effects of Eplerenone on Markers of Myocardial Fibrosis in Adult Congenital Heart Disease
NCT01971593 ·Status: TERMINATED ·Phase: PHASE4
-
Pharmacokinetics of Bisoprolol and SGLT2i in Acutely Decompensated Heart Failure
NCT06453577 ·Status: ACTIVE_NOT_RECRUITING
-
sPERMIdine supplemenTation on Metabolic, Neuronal and Cardiovascular Response to Exercise TRAINING
NCT05128331 ·Status: UNKNOWN ·Phase: NA